Browse by author
Lookup NU author(s): Dr Pasquale RescignoORCiD
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.The first-line therapy of metastatic renal cell carcinoma (mRCC) has revolutionized with the approval of immune checkpoint inhibitors (ICIs) in combination with or without tyrosine kinase inhibitors (TKIs). The choice among the many different immuno-combinations (ICI-ICI or ICI-TKI) is challenging due to the lack of predictive factors. The different shapes of the Kaplan–Meier survival curves (e.g. “banana-shaped curves”) have raised many questions on the long-term survival benefit. Here, we analyzed the factors that could have impacted the different long-term survival, including the prognostic factors distribution (IMDC score), histological factors (sarcomatoid features, PD-L1 expression), and treatment characteristics (mechanism of action, duration, discontinuation rate). This overview highlights the factors that should be considered in the first-line setting for the patients’ therapeutic choice and prognostic assessment. They are also fundamental parameters to examined for head-to-head studies and real-life, large-scale studies.
Author(s): Rebuzzi SE, Fornarini G, Signori A, Rescigno P, Banna GL, Buti S
Publication type: Note
Publication status: Published
Journal: Human Vaccines and Immunotherapeutics
Year: 2024
Volume: 20
Issue: 1
Online publication date: 17/05/2024
Acceptance date: 02/05/2024
ISSN (print): 2164-5515
ISSN (electronic): 2164-554X
Publisher: Taylor and Francis Ltd.
URL: https://doi.org/10.1080/21645515.2024.2351669
DOI: 10.1080/21645515.2024.2351669
PubMed id: 38757563
